After Fentanyl: The DEA Just Scheduled Another Ketamine Analog. Here’s What’s Already Replacing It.

On May 22, 2026, the Drug Enforcement Administration temporarily placed 2-fluorodeschloroketamine — known in harm reduction circles as 2-FDCK — in Schedule I of the Controlled Substances Act, effective for two years. The basis: imminent hazard to public safety. Clinical presentation ranges from hallucinogenic adverse effects to death. The DEA has seen this before: 2-FDCK is a structural analog of ketamine, designed to produce the dissociative effects of its parent compound while technically remaining outside the scheduled drug framework — until it doesn’t.

The scheduling of 2-FDCK is a routine move in a cycle that has played out dozens of times in the past decade. A novel compound appears in the drug supply. Toxicologists identify it in overdose cases. The DEA triggers an emergency scheduling action. The supply shifts to the next analog, already waiting.

What’s different about mid-2026 is the breadth of what’s shifting simultaneously — and the degree to which harm reduction infrastructure built around fentanyl is inadequate to the supply that’s replacing it.

The Nitazene Expansion

Nitazenes are a class of synthetic opioids that were synthesized in the 1950s and never approved for medical use. They were largely absent from street drug supplies until around 2019, when isotonitazene began appearing in toxicology cases in the US, Canada, and Europe. Since then, the proliferation has been rapid.

UNODC’s February 2026 bulletin identifies 34 nitazene analogues reported across 37 countries. Some of these compounds are reported to be hundreds to thousands of times more potent than morphine — and, in some cases, stronger than fentanyl. They’ve been detected in pills pressed to resemble oxycodone, in powders sold as heroin, and as adulterants in stimulant supplies. People who don’t intend to use synthetic opioids are being exposed to them.

Filter Magazine’s analysis pushes back on the dominant media framing that nitazenes are “more deadly than fentanyl” as a category — the actual potency varies enormously across the 34 known analogues, and the evidence base for harm reduction around nitazenes is still thin. But the directional problem is clear: the existing naloxone-based response to opioid overdose works for nitazenes (they bind to the same mu-opioid receptors), which means the priority is ensuring that people likely to encounter them have naloxone and know to use it. What makes nitazenes particularly dangerous is that the lethal dose range is so narrow and variable across analogues that even experienced opioid users can’t gauge risk from the usual proxies — how much they normally take, how they feel at a given dose.

Currently available fentanyl test strips do not detect most nitazenes. A fentanyl-negative test result does not mean opioid-free.

Medetomidine: The New Adulterant Nobody Is Testing For

The “Year in Drugs 2025” report from Opioid Data — compiled with Filter Magazine’s investigative coverage — identifies medetomidine as the most concerning new entrant in the opioid supply. Medetomidine is a veterinary sedative in the same class as xylazine (both are alpha-2 adrenergic agonists), but with some key differences: it’s more potent, more rapidly acting, and the withdrawal syndrome it produces is not fully characterized in humans.

When xylazine began appearing in fentanyl supplies several years ago, the harm reduction community developed specific responses: wound care protocols (xylazine causes severe, slow-healing skin wounds), guidance on how it complicates buprenorphine inductions, and naloxone education clarifying that naloxone reverses the fentanyl component but not the xylazine sedation. Test strips for xylazine became available, albeit unevenly distributed.

The concern with medetomidine is that the crackdown on xylazine — tightened veterinary supply chains, law enforcement focus — is driving supply toward medetomidine. And the harm reduction infrastructure doesn’t yet have medetomidine test strips. The toxidrome (clinical overdose presentation) is similar, but “similar” in this context means that people may not survive long enough to learn the differences.

The concern with medetomidine is that the crackdown on xylazine — tightened veterinary supply chains, law enforcement focus — is driving supply toward medetomidine.

What Scheduling Accomplishes (and What It Doesn’t)

The DEA’s 2-FDCK scheduling action is a legal move, not a public health intervention. Temporary Schedule I placement makes possession and distribution without authorization unlawful, which matters for prosecution but has a limited effect on availability. The manufacturers of 2-FDCK are not operating in jurisdictions where the US Controlled Substances Act applies. The product moves online through international mail. By the time the DEA schedules a compound and enforcement ramps up, the supply chains have already adapted.

This is not an argument against scheduling — but it is an argument against treating scheduling as a primary harm reduction strategy. The DEA’s own published analyses acknowledge that temporary scheduling tends to displace use toward the next analog rather than eliminating it.

What would actually reduce harm from 2-FDCK and similar dissociative analogs: test strips (which don’t currently exist for 2-FDCK in widely available formats), drug checking services (either fentanyl-test-strip distribution points or mass spectrometry-based services now operating in some US cities), and public education about the fact that what’s sold as “research chemicals” or “designer dissociatives” online carries unpredictable risk.

The Structural Problem

The novel-emerging drug supply is proliferating faster than any regulatory or clinical infrastructure can track it. UNODC counts 34 nitazene analogues. The DEA schedules one dissociative analog; three more are already in the synthesis pipeline. Medetomidine enters the opioid supply before harm reduction organizations have tests for it.

The fentanyl response — however incomplete — at least had the advantage of a single, stable chemical target. Fentanyl test strips work because fentanyl’s chemistry is consistent. The post-fentanyl supply is structurally resistant to this approach. Novel analogs can vary enough that test strips calibrated for one compound miss another in the same class.

Drug checking services — point-of-care mass spectrometry or Fourier-transform infrared spectroscopy that can identify unknown compounds — are the logical next-generation harm reduction tool. They’re expensive, they require trained operators, and they occupy a legally ambiguous space in most US jurisdictions. Several cities (Portland, San Francisco, New York) have piloted them with support from state-level harm reduction funding. None of those pilots were funded by SAMHSA, which in April 2026 banned federal funding for drug-checking supplies along with fentanyl test strips.

The gap between what the supply is doing and what the response infrastructure can handle has never been wider.